- Latest available (Revised)
- Point in Time (05/04/2017)
- Original (As adopted by EU)
Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU (Text with EEA relevance)
When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.
Legislation.gov.uk publishes the UK version. EUR-Lex publishes the EU version. The EU Exit Web Archive holds a snapshot of EUR-Lex’s version from IP completion day (31 December 2020 11.00 p.m.).
There are currently no known outstanding effects by UK legislation for Regulation (EU) 2017/746 of the European Parliament and of the Council.
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
Article 34.Application by conformity assessment bodies for designation
Article 36.Nomination of experts for joint assessment of applications for notification
Article 39.Identification number and list of notified bodies
Article 41.Review of notified body assessment of technical documentation and performance evaluation documentation
Article 44.Peer review and exchange of experience between authorities responsible for notified bodies
CHAPTER V CLASSIFICATION AND CONFORMITY ASSESSMENT
CHAPTER VI CLINICAL EVIDENCE, PERFORMANCE EVALUATION AND PERFORMANCE STUDIES
Article 57.General requirements regarding performance studies
Article 58.Additional requirements for certain performance studies
Article 62.Performance studies on pregnant or breastfeeding women
Article 70.Performance studies regarding devices bearing the CE marking
Article 72.Corrective measures to be taken by Member States and information exchange between Member States on performance studies
Article 73.Information from the sponsor at the end of a performance study or in the event of a temporary halt or early termination
Article 74.Coordinated assessment procedure for performance studies
Article 76.Recording and reporting of adverse events that occur during performance studies
CHAPTER VII POST-MARKET SURVEILLANCE, VIGILANCE AND MARKET SURVEILLANCE
CHAPTER IX CONFIDENTIALITY, DATA PROTECTION, FUNDING AND PENALTIES
VI Information to be submitted upon the registration of devices and...
IX Conformity assessment based on a quality management system and on...
XI Conformity assessment based on production quality assurance
XIII Performance evaluation, performance studies and post-market performance follow-up
XIV Interventional clinical performance studies and certain other performance studies
GENERAL SAFETY AND PERFORMANCE REQUIREMENTS
CHAPTER I GENERAL REQUIREMENTS
1. Devices shall achieve the performance intended by their manufacturer and...
3. Manufacturers shall establish, implement, document and maintain a risk management...
4. Risk control measures adopted by manufacturers for the design and...
5. In eliminating or reducing risks related to use error, the...
6. The characteristics and performance of a device shall not be...
7. Devices shall be designed, manufactured and packaged in such a...
8. All known and foreseeable risks, and any undesirable effects shall...
CHAPTER II REQUIREMENTS REGARDING PERFORMANCE, DESIGN AND MANUFACTURE
11. Infection and microbial contamination
11.1. Devices and their manufacturing processes shall be designed in such...
11.2. Devices labelled either as sterile or as having a specific...
11.3. Devices labelled as sterile shall be processed, manufactured, packaged and,...
11.4. Devices intended to be sterilised shall be manufactured and packaged...
11.5. Packaging systems for non-sterile devices shall maintain the integrity and...
11.6. The labelling of the device shall distinguish between identical or...
13. Construction of devices and interaction with their environment
13.1. If the device is intended for use in combination with...
13.2. Devices shall be designed and manufactured in such a way...
13.3. Devices shall be designed and manufactured in such a way...
13.4. Devices shall be designed and manufactured in such a way...
13.5. Devices that are intended to be operated together with other...
13.6. Devices shall be designed and manufactured in such a way...
13.7 The measuring, monitoring or display scale (including colour change and...
16. Electronic programmable systems — devices that incorporate electronic programmable systems...
16.1. Devices that incorporate electronic programmable systems, including software, or software...
16.2. For devices that incorporate software or for software that are...
16.3. Software referred to in this Section that is intended to...
16.4. Manufacturers shall set out minimum requirements concerning hardware, IT networks...
17. Devices connected to or equipped with an energy source
17.1. For devices connected to or equipped with an energy source,...
17.2. Devices where the safety of the patient depends on an...
17.3. Devices shall be designed and manufactured in such a way...
17.4. Devices shall be designed and manufactured in such a way...
17.5. Devices shall be designed and manufactured in such a way...
18. Protection against mechanical and thermal risks
18.1. Devices shall be designed and manufactured in such a way...
18.2. Devices shall be sufficiently stable under the foreseen operating conditions....
18.3. Where there are risks due to the presence of moving...
18.4. Devices shall be designed and manufactured in such a way...
18.5. Devices shall be designed and manufactured in such a way...
18.6. Terminals and connectors to the electricity, gas or hydraulic and...
18.7. Errors likely to be made when fitting or refitting certain...
18.8. Accessible parts of devices (excluding the parts or areas intended...
19. Protection against the risks posed by devices intended for self-testing...
CHAPTER III REQUIREMENTS REGARDING INFORMATION SUPPLIED WITH THE DEVICE
The technical documentation and, if applicable, the summary thereof to...
1. DEVICE DESCRIPTION AND SPECIFICATION, INCLUDING VARIANTS AND ACCESSORIES
3.2. Shipping containers shall be exempted from the requirement in Section...
3.5. If a lot number, serial number, software identification or expiry...
3.6. Each component that is considered to be a device and...
3.8. The manufacturer shall assign the UDI to a device following...
3.10. Manufacturers that repackage or relabel devices with their own label...
4.1. The UDI carrier (AIDC and HRI representation of the UDI)...
4.2. In the event of there being significant space constraints on...
4.4. For devices exclusively intended for retail point of sale, the...
4.5. When AIDC carriers other than the UDI carrier are part...
4.7. If there are significant constraints limiting the use of both...
4.9. If the manufacturer is using RFID technology, a linear or...
4.10. Devices that are reusable shall bear a UDI carrier on...
4.11. The UDI carrier shall be readable during normal use and...
4.12. If the UDI carrier is readily readable or scannable through...
5. General principles of the UDI database
5.2. Manufacturers shall be responsible for the initial submission and updates...
5.3. Appropriate methods/procedures for validation of the data provided shall be...
5.4. Manufacturers shall periodically verify the correctness of all of the...
5.5. The presence of the device UDI-DI in the UDI database...
5.8. Manufacturers shall update the relevant UDI database record within 30...
5.9. Internationally accepted standards for data submission and updates shall, wherever...
5.10. The user interface of the UDI database shall be available...
5.11. Data relating to devices that are no longer available on...
REQUIREMENTS TO BE MET BY NOTIFIED BODIES
1. ORGANISATIONAL AND GENERAL REQUIREMENTS
1.2. Independence and impartiality
1.2.1. The notified body shall be a third-party body that is...
1.2.2. The notified body shall be organised and operated so as...
1.2.3. The notified body, its top-level management and the personnel responsible...
1.2.4. Involvement in consultancy services in the field of devices prior...
1.2.5. The impartiality of notified bodies, of their top-level management and...
1.2.7. The notified body shall ensure and document that the activities...
1.2.8. The notified body shall operate in accordance with a set...
1.2.9. The requirements laid down in this Section shall in no...
3.2. Qualification criteria in relation to personnel
3.2.1. The notified body shall establish and document qualification criteria and...
3.2.2. The qualification criteria referred to in Section 3.2.1 shall refer...
3.2.3. The personnel responsible for establishing qualification criteria and for authorising...
3.2.4. The notified body shall have permanent availability of personnel with...
3.2.5. The personnel responsible for carrying out product-related reviews, (product reviewers),...
3.2.6. The personnel responsible for carrying out audits of the manufacturer's...
3.2.7. The personnel with overall responsibility for final reviews and decision-making...
3.3. Documentation of qualification, training and authorisation of personnel
3.5. Monitoring of competences, training and exchange of experience
1.1. Application of the classification rules shall be governed by the...
1.3. Accessories for an in vitro diagnostic medical device shall be...
1.4. Software, which drives a device or influences the use of...
1.5. Calibrators intended to be used with a device shall be...
1.6. Control materials with quantitative or qualitative assigned values intended for...
1.7. The manufacturer shall take into consideration all classification and implementation...
1.8. Where a manufacturer states multiple intended purposes for a device,...
1.9. If several classification rules apply to the same device, the...
1.10. Each of the classification rules shall apply to first line...
CHAPTER I QUALITY MANAGEMENT SYSTEM
1. The manufacturer shall establish, document and implement a quality management...
3. Surveillance assessment applicable to class C and class D devices...
3.1. The aim of surveillance is to ensure that the manufacturer...
3.2. The manufacturer shall give authorisation to the notified body to...
3.3. Notified bodies shall periodically, at least once every 12 months,...
3.4. The notified body shall randomly perform at least once every...
3.5. In the case of class C devices, the surveillance assessment...
3.6. Notified bodies shall ensure that the composition of the assessment...
3.7. If the notified body finds a divergence between the sample...
CHAPTER II ASSESSMENT OF THE TECHNICAL DOCUMENTATION
4. Assessment of the technical documentation of class B, C and...
4.1. In addition to the obligation laid down in Section 2,...
4.2. The application shall describe the design, manufacture and performance of...
4.3. The notified body shall examine the application by using staff,...
4.4. The notified body shall review the clinical evidence presented by...
4.5. The notified body shall, in circumstances in which the clinical...
4.6. The notified body shall verify that the clinical evidence and...
4.7. Based on its assessment of the clinical evidence, the notified...
4.8. The notified body shall clearly document the outcome of its...
4.9. Before issuing an EU technical documentation assessment certificate, the notified...
4.10. The notified body shall provide the manufacturer with a report...
4.11. Changes to the approved device shall require approval from the...
4.12. To verify conformity of manufactured class D devices, the manufacturer...
4.13. The manufacturer may place the devices on the market, unless...
5. Assessment of the technical documentation of specific types of devices...
CONFORMITY ASSESSMENT BASED ON TYPE-EXAMINATION
1. EU type-examination is the procedure whereby a notified body ascertains...
5.1. The applicant shall inform the notified body which issued the...
5.2. Changes to the approved device including limitations of its intended...
5.3. Changes to the intended purpose and conditions of use of...
5.4. Where the changes could affect the performance claimed by the...
5.5. Where the changes affect the performance or the intended use...
PERFORMANCE EVALUATION, PERFORMANCE STUDIES AND POST-MARKET PERFORMANCE FOLLOW-UP
PART B POST-MARKET PERFORMANCE FOLLOW-UP
4. PMPF shall be understood to be a continuous process that...
5. PMPF shall be performed pursuant to a documented method laid...
6. The manufacturer shall analyse the findings of the PMPF and...
7. The conclusions of the PMPF evaluation report shall be taken...
8. If PMPF is not deemed appropriate for a specific device...
INTERVENTIONAL CLINICAL PERFORMANCE STUDIES AND CERTAIN OTHER PERFORMANCE STUDIES
The Whole Regulation you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Schedules you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As adopted by EU): The original version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.
Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
This timeline shows the different versions taken from EUR-Lex before exit day and during the implementation period as well as any subsequent versions created after the implementation period as a result of changes made by UK legislation.
The dates for the EU versions are taken from the document dates on EUR-Lex and may not always coincide with when the changes came into force for the document.
For any versions created after the implementation period as a result of changes made by UK legislation the date will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. For further information see our guide to revised legislation on Understanding Legislation.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including:
The data on this page is available in the alternative data formats listed: